Home Applications 020173 Application 020173
Type NDA
Sponsor BAXTER HLTHCARE Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE INJECTABLE;INJECTION 5.5%;102MG/100ML;522MG/100ML;431MG/100ML;224MG/100ML No No 002 TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE INJECTABLE;INJECTION 8.5%;102MG/100ML;522MG/100ML;594MG/100ML;154MG/100ML No No
Source provenance: Browse the complete Orange Book source catalog · source snapshot 44 .
Orange Book products# Current product rows page 1 of 1 · 2 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N020173-001 TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE 5.5%;102MG/100ML;522MG/100ML;431MG/100ML;224MG/100ML INJECTABLE / INJECTION 1995-10-27 N020173-002 TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE 8.5%;102MG/100ML;522MG/100ML;594MG/100ML;154MG/100ML INJECTABLE / INJECTION 1995-10-27
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 3 of 3 · 88 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2022-10-28 04:53 UTC 2022-10 N020173-001 TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER 5.5%;102MG/100ML;522MG/100ML;431MG/100ML;224MG/100ML INJECTABLE / INJECTION 1995-10-27 f41ea6bd6efb…2022-10-28 04:53 UTC 2022-10 N020173-002 TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER 8.5%;102MG/100ML;522MG/100ML;594MG/100ML;154MG/100ML INJECTABLE / INJECTION 1995-10-27 f41ea6bd6efb…2022-09-29 23:25 UTC 2022-09 N020173-001 TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER 5.5%;102MG/100ML;522MG/100ML;431MG/100ML;224MG/100ML INJECTABLE / INJECTION 1995-10-27 e64feba35796…2022-09-29 23:25 UTC 2022-09 N020173-002 TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER 8.5%;102MG/100ML;522MG/100ML;594MG/100ML;154MG/100ML INJECTABLE / INJECTION 1995-10-27 e64feba35796…2022-07-09 03:26 UTC · 3 captures of this ZIP 2022-07 N020173-001 TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER 5.5%;102MG/100ML;522MG/100ML;431MG/100ML;224MG/100ML INJECTABLE / INJECTION 1995-10-27 cb3db0bc1861…2022-07-09 03:26 UTC · 3 captures of this ZIP 2022-07 N020173-002 TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER 8.5%;102MG/100ML;522MG/100ML;594MG/100ML;154MG/100ML INJECTABLE / INJECTION 1995-10-27 cb3db0bc1861…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N020173-001 TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER 5.5%;102MG/100ML;522MG/100ML;431MG/100ML;224MG/100ML INJECTABLE / INJECTION 1995-10-27 a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N020173-002 TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER 8.5%;102MG/100ML;522MG/100ML;594MG/100ML;154MG/100ML INJECTABLE / INJECTION 1995-10-27 a50c72e98297…
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.